Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects.
about
Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indicationsClinical pharmacokinetic and pharmacodynamic profile of rivaroxabanUse of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.Rivaroxaban: a review of its use in acute coronary syndromes.Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.Drug-drug interactions of non-vitamin K oral anticoagulants.Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know.Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.Acute pulmonary embolism: risk assessment, risk stratification and treatment options.The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.
P2860
Q26828817-7D76AE31-5179-4A32-A542-052DB417AA2EQ26864411-A5F7CF4B-0AE1-4CFA-BFA9-53E4C75D8596Q37257471-D68C11F5-D22E-438F-831D-34ECCF411C2DQ38175211-9F31ADE6-5363-4199-9DC1-834DC63F212CQ38188899-2872604E-7199-4C7B-8765-10E2F0219B09Q38740354-ED7BCFBF-63D9-4232-9628-F3293E602A32Q38830358-175D4188-CDA4-4E67-8007-B1902F21D01DQ39023182-08896D83-A839-4B47-AD70-629528CAD433Q39041243-D57C77D5-6953-4322-A22B-A1AF9B7BC053Q50504217-5164350B-63F4-4FBF-8450-37C59F219C2EQ51150941-A72BD353-9493-4D59-8653-7E2B6D29C58EQ54961174-B2B8DEA3-32E8-4EF9-B653-3DA3FC2FC82B
P2860
Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@en
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@nl
type
label
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@en
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@nl
prefLabel
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@en
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@nl
P2093
P2860
P356
P1476
Investigation of Pharmacodynam ...... arin in Healthy Male Subjects.
@en
P2093
Barbara Voith
Dagmar Kubitza
Michael Becka
Stephan Schwers
P2860
P304
P356
10.1002/CPDD.26
P577
2013-05-15T00:00:00Z